A Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination with Nivolumab to Subjects with Locally Advanced or Metastatic Solid Tumors
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Mereo BioPharma Group
Start Date
May 27, 2021
End Date
June 14, 2026
Administered By
Duke Cancer Institute
Awarded By
Mereo BioPharma Group
Start Date
May 27, 2021
End Date
June 14, 2026